ii) Primary culture of satellite cells with 5 ng/ml HGF, which received only the LASSS pre-treatment (at 1:8000, without peroxynitrite treatment), exhibited a cell-proliferation activity (evaluated by mRNA expression levels of MyoD and its counter-regulatory factor myogenin at 48-h and 72-h time-points) comparable to that of the positive control culture treated with 5 ng/ml control HGF without LASSS (just with the solvent
These options are separate from mobile IV booking and can be explored through the shop.
CrossRef GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Nadia Sawicka-Gutaj, Dawid Gruszczyski, Kacper Nijakowski, Aleksandra Derwich-Rudowicz, Michal Krenz, Anita Kumar, Pei-Yin Lu, Marek Ruchaa International Journal of Obesity.2026;[Epub] CrossRef Metabolic DysfunctionAssociated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef Intravenous contrast medium impairs CT-based muscle quality but not quantity assessment: a translational study Luca Salhfer, Gregor Jost, Mathias Holtkamp, Jannis Straus, Marcel Opitz, Sebastian Zensen, Rene Hosch, Johannes Harmes, Lale Umutlu, Michael Forsting, Felix Nensa, Hubertus Pietsch, Johannes Haubold Frontiers in Radiology.2026;[Epub] CrossRef Nanotechnology-enabled targeted delivery of incretin therapies for the treatment of obesity and metabolic disorders Daniel Ejim Uti, Josephine E
10.1186/s13024-019-0341-5 [DOI] [PMC free article] [PubMed] [Google Scholar] Trenz T
NeuroImage 293:120632
